Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W L Dahut

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 12, 2009
About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?J B Aragon-Ching, W L Dahut
The New England Journal of Medicine|November 5, 1992
Fludarabine and acute tumor lysis in chronic lymphocytic leukemiaJ N Frame, W L Dahut, S Crowley
Southern Medical Journal|December 31, 1997
Renal angiosarcoma: a rare primary genitourinary malignancyR M Mordkin, W L Dahut, J H Lynch
Biochimica Et Biophysica Acta|August 24, 1999
Review of AACR meeting: new research approaches in the prevention and cure of prostate cancer, 2-6 December 1998, Indian Wells, CAD K Ornstein, W L Dahut, L A Liotta, et al.
Bone Marrow Transplantation|December 1, 1994
Late extramedullary relapse following bone marrow transplant for AML presenting as acute renal failure and leukemic ascitesD A Riseberg, K P Mulvey, W L Dahut, et al.
Journal of Chromatography. B, Biomedical Applications|April 22, 1994
Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatographyC H Takimoto, R W Klecker, W L Dahut, et al.
Transfusion|September 1, 1992
Geographic risk factors for viral hepatitis and cytomegalovirus infection among United States Armed Forces blood donorsK C Hyams, E R Cross, M A Bianco, et al.
Seminars in Oncology|October 31, 2001
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancerW D Figg, P Arlen, J Gulley, et al.
The Pharmacogenomics Journal|December 30, 2009
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platformJ F Deeken, T Cormier, D K Price, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2017
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweetA J Armstrong, E S Antonarakis, M-E Taplin, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 12, 2009
About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?J B Aragon-Ching, W L Dahut
The New England Journal of Medicine|November 5, 1992
Fludarabine and acute tumor lysis in chronic lymphocytic leukemiaJ N Frame, W L Dahut, S Crowley
Southern Medical Journal|December 31, 1997
Renal angiosarcoma: a rare primary genitourinary malignancyR M Mordkin, W L Dahut, J H Lynch
Biochimica Et Biophysica Acta|August 24, 1999
Review of AACR meeting: new research approaches in the prevention and cure of prostate cancer, 2-6 December 1998, Indian Wells, CAD K Ornstein, W L Dahut, L A Liotta, et al.
Bone Marrow Transplantation|December 1, 1994
Late extramedullary relapse following bone marrow transplant for AML presenting as acute renal failure and leukemic ascitesD A Riseberg, K P Mulvey, W L Dahut, et al.
Journal of Chromatography. B, Biomedical Applications|April 22, 1994
Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatographyC H Takimoto, R W Klecker, W L Dahut, et al.
Transfusion|September 1, 1992
Geographic risk factors for viral hepatitis and cytomegalovirus infection among United States Armed Forces blood donorsK C Hyams, E R Cross, M A Bianco, et al.
Seminars in Oncology|October 31, 2001
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancerW D Figg, P Arlen, J Gulley, et al.
The Pharmacogenomics Journal|December 30, 2009
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platformJ F Deeken, T Cormier, D K Price, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2017
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweetA J Armstrong, E S Antonarakis, M-E Taplin, et al.
Pageof 1